Together, the results suggest that a monoclonal antibody that targets the IL-6 receptor might prevent pathogenic conversion of Tregs and re-establish regulatory function in T1D, thereby interrupting immune-mediated destruction of insulin-secreting β-cells. Here, INS is linked to type 1 diabetes mellitus.